Treatment of primary biliary cirrhosis with tetrathiomolybdate: results of a double-blind trial

Translational Research

Volumn 155, Issue 3, 2010, Pages 123-130

  Askari, Fred ^a   Innis, Dawna ^a   Dick, Robert B ^a   Hou, Guoqing ^a   Marrero, Jorge ^a   Greenson, Joel ^a   Brewer, George J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERULOPLASMIN; CYTOKINE; PLACEBO; TETRATHIOMOLYBDIC ACID;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; BILE DUCT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER FUNCTION; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL;

EID: 76549123971     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2009.09.009     Document Type: Article

References (25)

1. Brewer G.J., Hedera P., Kluin K.J., et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 60 (2003) 379-385
2. Brewer G.J., Askari F., Lorincz M.T., et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 63 (2006) 521-527
3. Brewer G.J. Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer. Curr Cancer Drug Targets 5 (2005) 195-202
4. Brewer G.J., Dick R.D., Grover D.K., et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin Cancer Res 6 (2000) 1-10
5. Pass H.I., Brewer G.J., Dick R., Carbone M., and Merajver S. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg 86 (2008) 383-389
6. Brewer G.J., Ullenbruch M.R., Dick R.B., Olivarez L., and Phan S.H. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med 141 (2003) 210-216
7. Brewer G.J., Dick R., Ullenbruch M.R., Jin H., and Phan S.H. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem 98 (2004) 2160-2167
8. Askari F.K., Dick R.B., Mao M., and Brewer G.J. Tetrathiomolybdate therapy protects against concanavalin A and carbon tetrachloride hepatic damage in mice. Exp Bio Med 229 (2004) 857-863
9. Ma S., Hou G., Dick R.D., and Brewer G.J. Tetrathiomolybdate protects against liver injury from acetaminophen in mice. J Appl Res Clin Exp Ther 4 (2004) 419-426
10. Song M., Song Z., Barve S., et al. Tetrathiomolybdate protects against bile duct ligation-induced cholestatic liver injury and fibrosis. J Pharmacol Exp Ther 325 (2008) 409-416
11. Flaherty KR, Arenberg DA, White ES, et al. Treatment of idiopathic pulmonary fibrosis with tetrathiomolybdate. In press.
12. Hou G., Dick R., Abrams G.D., and Brewer G.J. Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J Lab Clin Med 146 (2005) 299-303
13. Brewer G.J., Dick R., Zeng C., and Hou G. The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model. J Inorg Biochem 100 (2006) 927-930
14. McCubbin M.D., Hou G., Abrams G.D., Dick R., Zhang Z., and Brewer G.J. Tetrathiomolybdate is effective in a mouse model of arthritis. J Rheumatol 33 (2006) 2501-2506
15. Hou G., Abrams G., Dick R., and Brewer G.J. Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis. Transl Res 152 (2008) 239-244
16. Chung R.T., and Podolsky D.K. Cirrhosis and its complications: primary biliary cirrhosis. In: Braunwald E., Fauci A.S., Kasper D.L., Hauser S.L., Longo D.L., and Jameson J.L. (Eds). Harrison's principles of internal medicine. 15th ed (2001), McGraw-Hill, New York 1757-1758
17. Digestive Disease Interagency Coordinating Committee. Translational research in primary biliary cirrhosis. Available at: http://www2.niddk.nih.gov/NR/rdonlyres/8FC7A357-1BA5-4068-9B6D-AA012EA3FD3D/0/DDICC_June_16_2003_Minutes.pdf. Accessed November 19, 2007.
18. Pyrsopoulos NT, Reddy KR, Wu GY, et al. Primary biliary cirrhosis. Available at: http://www.emedicine.com/MED/topic223.htm. Accessed December 11, 2008.
19. Colucci G., Schaffner F., and Paronetto F. In situ characterization of the cell-surface antigens of the mononuclear cell infiltrate and bile duct epithelium in primary biliary cirrhosis. Clin Immunol Immunopathol 41 (1986) 35-42
20. Kaplan M.M. Primary biliary cirrhosis. N Engl J Med 335 (1996) 1570-1580
21. Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med 357 (2007) 1524-1529
22. Gartner E.M., Griffith K.A., Pan Q., et al. A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. Invest New Drugs 27 (2009) 159-165
23. Henry N.L., Dunn R., Merjaver S., et al. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone refractory prostate cancer. Oncology 71 (2006) 168-175
24. Redman B.G., Esper P., Pan Q., et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 9 (2003) 1666-1672
25. Vine A.K., and Brewer G.J. Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Trans Am Ophthalmol Soc 100 (2002) 73-76